Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has received a consensus rating of “Moderate Buy” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation […]
More Stories
StockNews.com Downgrades Brightcove (NASDAQ:BCOV) to Buy
StockNews.com cut shares of Brightcove (NASDAQ:BCOV – Free Report) from a strong-buy rating to a buy rating in a research...
StockNews.com Upgrades Team (NYSE:TISI) to “Strong-Buy”
StockNews.com upgraded shares of Team (NYSE:TISI – Free Report) from a buy rating to a strong-buy rating in a research...
Chicago Rivet & Machine (NYSEAMERICAN:CVR) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Chicago Rivet & Machine (NYSEAMERICAN:CVR – Free Report) in a report published on Wednesday...
Aeries Technology (AERT) & Its Competitors Head-To-Head Comparison
Profitability This table compares Aeries Technology and its peers’ net margins, return on equity and return on assets. Net Margins...
Insider Selling: Secure Energy Services Inc. (TSE:SES) Insider Sells 2,995 Shares of Stock
Secure Energy Services Inc. (TSE:SES – Get Free Report) insider David Bonderman sold 2,995 shares of the company’s stock in...
Tensions Rise Over ICC Arrest Warrants for Netanyahu, Gallant as US Allies Mull Response
By Tom Ozimek Controversy is intensifying and the stakes are rising over the International Criminal Court’s (ICC) recent decision to...